Literature DB >> 8147175

[Evaluation of climacteric symptoms (Menopause Rating Scale)].

G A Hauser1, I C Huber, P J Keller, C Lauritzen, H P Schneider.   

Abstract

Quantification and qualification of climacteric symptoms had been described by Kupperman et al in 1953. New findings and ideas in the following forty years needed a correction of Kupperman index. Two important groups reduced the essential symptoms only on two ones, vasomotoric hot flushes and genital atrophy. On the contrary, Menopause Rating Scale (MRS) presented here enables registration of so called psychic symptoms, too, essential for quality of life. Complaint from bladder and urethra, hints and muscles and sexual disorders are also registered. For each of the ten symptom groups there is a rating scale from 0.0 (no symptoms) to 1.0 (very strong symptoms), in a graphic, too. In this way an individual profile will be visible. Using MRC it is possible, to quantify a better or worst status during and after treatment and to depict it.

Entities:  

Mesh:

Year:  1994        PMID: 8147175

Source DB:  PubMed          Journal:  Zentralbl Gynakol        ISSN: 0044-4197


  27 in total

Review 1.  Non-hormonal treatment strategies for vasomotor symptoms: a critical review.

Authors:  Elise Hall; Benicio N Frey; Claudio N Soares
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 2.  Literature review of instruments to assess health-related quality of life during and after menopause.

Authors:  Y F Zöllner; C Acquadro; M Schaefer
Journal:  Qual Life Res       Date:  2005-03       Impact factor: 4.147

3.  Psychometric evaluation of the Midlife Women's Symptom Index in multiethnic groups.

Authors:  Bokim Lee; Eun-Ok Im; Wonshik Chee
Journal:  West J Nurs Res       Date:  2010-07-06       Impact factor: 1.967

Review 4.  Chinese herbal medicine for menopausal symptoms.

Authors:  Xiaoshu Zhu; Yuklan Liew; Zhao Lan Liu
Journal:  Cochrane Database Syst Rev       Date:  2016-03-15

5.  Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography.

Authors:  Paraskevi Vivien Rekkas; Alan A Wilson; Vivian Wai Han Lee; Priyanga Yogalingam; Julia Sacher; Pablo Rusjan; Sylvain Houle; Donna E Stewart; Nathan J Kolla; Stephen Kish; Lina Chiuccariello; Jeffrey H Meyer
Journal:  JAMA Psychiatry       Date:  2014-08       Impact factor: 21.596

6.  Disorders of eating and body image during the menopausal transition: associations with menopausal stage and with menopausal symptomatology.

Authors:  Barbara Mangweth-Matzek; Claudia Ines Rupp; Sophia Vedova; Vanessa Dunst; Philine Hennecke; Martin Daniaux; Harrison G Pope
Journal:  Eat Weight Disord       Date:  2021-02-17       Impact factor: 4.652

7.  Frequency of symptoms, determinants of severe symptoms, validity of and cut-off score for Menopause Rating Scale (MRS) as a screening tool: a cross-sectional survey among midlife Nepalese women.

Authors:  Neena Chuni; Chandrashekhar T Sreeramareddy
Journal:  BMC Womens Health       Date:  2011-06-14       Impact factor: 2.809

8.  Anxiety, Depression, and Quality of Life After Procedural Intervention for Uterine Fibroids.

Authors:  Kedra Wallace; Elizabeth A Stewart; Lauren A Wise; Wanda Kay Nicholson; John Preston Parry; Shuaiqi Zhang; Shannon Laughlin-Tommaso; Vanessa Jacoby; Raymond M Anchan; Michael P Diamond; Sateria Venable; Amber Shiflett; Ganesa R Wegienka; George Larry Maxwell; Daniel Wojdyla; Evan R Myers; Erica Marsh
Journal:  J Womens Health (Larchmt)       Date:  2021-06-08       Impact factor: 2.681

9.  Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom.

Authors:  Marco Dacosta Dibonaventura; Arthi Chandran; Ming-Ann Hsu; Andrew Bushmakin
Journal:  Int J Womens Health       Date:  2013-05-24

10.  Correlation between the modified Kupperman Index and the Menopause Rating Scale in Chinese women.

Authors:  Minfang Tao; Hongfang Shao; Changbing Li; Yincheng Teng
Journal:  Patient Prefer Adherence       Date:  2013-03-20       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.